caa a22 4500 475823869 CHVBK 20180406123825.0 cr unu---uuuuu 170329e20000101xx s 000 0 eng 10.1023/A:1018631810977 doi (NATIONALLICENCE)springer-10.1023/A:1018631810977 Ticlopidine Enhances the Platelet Inhibitory Capacity of Abciximab In Vitro [Elektronische Daten] [Neal Kleiman, Nikki Graziadei, Robert Jordan, Ellen Lance, Anthony Fischer, Kelly Maresh, Amy Edwards, Mary Mascelli] Ticlopidine and abciximab are two antiplatelet agents that are frequently administered during percutaneous coronary interventions. Although they have different mechanisms of action and pharmacological profiles, the two agents are often concomitantly used in complicated stent placements. The purpose of the study was to evaluate the effect of ticlopidine therapy on the capacity of abciximab to inhibit platelet aggregation, in vitro. Blood samples from 13 ticlopidine-treated stent placement patients and 8 patients undergoing PTCA who did not receive ticlopidine were obtained prior to, 12-36 hours and 7-10 days after initiating ticlopidine treatment. For each patient, the minimal ADP and the thrombin receptor activating peptide (TRAP) concentrations that elicited maximal platelet aggregation responses at baseline were used to measure the extent of platelet aggregation and the abciximab concentration that gave a 50% decrease in aggregation (IC50) for both agonists at the three time points. The ticlopidine group baseline and 12-36 hour mean ADP aggregation responses were equivalent, but decreased by 34% (P = 0.009) at 7-10 days. The control group ADP and TRAP, as well as the ticlopidine group TRAP aggregation responses, were equivalent at all time points. The ticlopidine group baseline and 12-36 hour abciximab IC50 values for ADP were comparable (1.58 ± 1.1 ng/mL vs. 1.23 ± 0.5 ng/mL; P = 0.266), but decreased to 1.00 ± 0.6 ng/mL (36%; P = 0.004) at 7-10 days. In contrast, the abciximab IC50 for TRAP increased from 1.48 ± 1.0 ng/mL to 1.85 ± 1.1 ng/mL (25%; P = 0.033) at 12-36 hours, but returned to baseline at 7-10 days (1.40 ± 0.8; P = 0.975). The control group IC50 abciximab values for ADP and TRAP were comparable throughout the monitoring period. The results demonstrate that ticlopidine elicits subtle potentiation of the platelet-inhibitory capacity of abciximab to the agonist ADP, but not TRAP, at 1 week after initiation of treatment. Kluwer Academic Publishers, 2000 ticlopidine nationallicence abciximab nationallicence platelet inhibition nationallicence Kleiman Neal Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut Graziadei Nikki Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut Jordan Robert Centocor, Inc., Malvern, Pennsylvania, USA aut Lance Ellen Centocor, Inc., Malvern, Pennsylvania, USA aut Fischer Anthony Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut Maresh Kelly Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut Edwards Amy Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut Mascelli Mary Centocor, Inc., Malvern, Pennsylvania, USA aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 9/1(2000-01-01), 29-36 0929-5305 9:1<29 2000 9 11239 https://doi.org/10.1023/A:1018631810977 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018631810977 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kleiman Neal Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut NATIONALLICENCE 700 1- Graziadei Nikki Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut NATIONALLICENCE 700 1- Jordan Robert Centocor, Inc., Malvern, Pennsylvania, USA aut NATIONALLICENCE 700 1- Lance Ellen Centocor, Inc., Malvern, Pennsylvania, USA aut NATIONALLICENCE 700 1- Fischer Anthony Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut NATIONALLICENCE 700 1- Maresh Kelly Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut NATIONALLICENCE 700 1- Edwards Amy Baylor College of Medicine and the Methodist Hospital, Houston, Texas aut NATIONALLICENCE 700 1- Mascelli Mary Centocor, Inc., Malvern, Pennsylvania, USA aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 9/1(2000-01-01), 29-36 0929-5305 9:1<29 2000 9 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer